Medicalgorithmics S.A., a technology company developing advanced solutions for cardiac diagnostics, is progressing with two strategic research projects aimed at expanding the clinical and commercial use of artificial intelligence in cardiac monitoring: AI VESPER and GIMLET.
According to the company's strategic research pipeline, AI VESPER focuses on validating AI autonomy in arrhythmia diagnostics, while GIMLET is designed to support mass-market prevention through low-cost tools for general practitioners and wearable devices. The projects are part of Medicalgorithmics' effort to define the next standard of care through clinical research and scalable AI-based software development.
AI VESPER is a randomized, blinded clinical trial comparing independent AI-generated reporting with reporting performed by human technicians. The goal is to demonstrate the safety of fully automated diagnostics and support the development of Medicalgorithmics' second generation of highly specialized, automated arrhythmia diagnostics platform. The project has already received IRB approval. Medicalgorithmics is developing the software tools required for the study, while PHRI in Canada is working with hospitals to enroll participants and finalize arrangements with study sites.
The business potential of AI VESPER is tied to the automation of a large and growing cardiac monitoring market. The global cardiac monitoring devices market is expected to reach about USD 31.60 billion by 2032, while the broader cardiac monitoring and cardiac rhythm management devices market is projected to reach USD 37.88 billion by 2031.
Within this market, AI-based cardiac diagnostics is growing even faster. The cardiac AI monitoring and diagnostics segment at approximately at expected annual growth of more than 26.9% to 2032 CAGR.
For Medicalgorithmics, successful validation of AI VESPER could support a business model based on higher automation, lower manual review intensity, faster report turnaround and improved scalability across geographies. In practical terms, the project may strengthen the company's position in software-driven diagnostic services, where each additional monitored patient can be analyzed with a lower incremental operational burden than in technician-heavy workflows.
GIMLET, the second project in the pipeline, is focused on mass-market prevention. It is being developed as a low-cost solution for general practitioners and wearable devices to detect atrial fibrillation and other cardiac abnormalities in general populations. The project emphasizes prevention and long-duration monitoring. Medicalgorithmics is currently working on a software prototype, which is ahead of the original schedule and expected to be tested in the coming weeks. The prototype already leverages DRAI AI algorithms and is close in functionality to a production version.
The commercial opportunity for GIMLET is driven by the scale of atrial fibrillation and the expansion of wearable and ambulatory cardiac monitoring. A 2025 review reported that global atrial fibrillation prevalence nearly doubled over three decades. In the United States alone, atrial fibrillation prevalence is projected to rise to 12.1 million people by 2030.
GIMLET addresses a different commercial segment than AI VESPER: instead of focusing only on specialized diagnostic workflows, it targets primary care, population screening, wearables and preventive monitoring. The global wearable cardiac devices market is projected to grow to USD 8.5 billion by 2035, at a 12.2% CAGR. The ambulatory cardiac monitoring devices market is forecast to reach approximately USD 24.58 billion by 2035, growing at 11.19% CAGR.
For Medicalgorithmics, this creates potential for GIMLET to expand the company's addressable market from advanced arrhythmia diagnostics into earlier-stage detection and prevention. Potential commercial pathways include licensing to digital health platforms, partnerships with wearable device ecosystems, primary-care screening programs, pay-per-analysis models and recurring software-based revenue streams.
"These projects represent a targeted expansion of Medicalgorithmics' AI strategy," said [Name, Title], Medicalgorithmics S.A. "AI VESPER is designed to validate whether AI can safely perform more autonomous diagnostic reporting, while GIMLET aims to move cardiac monitoring closer to everyday care - including primary care and wearable-based prevention. Together, they address both sides of the market: efficiency in specialist diagnostics and scale in population-level screening."
AI VESPER and GIMLET position Medicalgorithmics at the intersection of clinical validation, automated diagnostics and preventive cardiac care. By combining research-grade validation with software scalability, the company is building a pipeline that may support earlier detection, improved workflow efficiency and access to larger global cardiac monitoring markets.
- June 22, 2026